Orion Oyj Stock Hits 52-Week High on Strong Nubeqa Sales and Upgraded Outlook

Shares of Orion Oyj B (ORNBV) surged 9.1% on Friday, reaching a new 52-week high of EUR 75.6 after the Finnish pharmaceutical company reported strong financial results for the first half of 2026 and raised its full-year outlook.

Nubeqa Royalties Fuel Earnings Beat

Orion announced a standout performance for the second quarter in its Half-Year Financial Report, significantly exceeding analyst expectations. The company's results were driven primarily by its prostate cancer drug, Nubeqa, which is co-commercialized with Bayer.

Key figures from the report include:

• Net Sales: Grew 25% year-over-year in the second quarter.
• Operating Profit: Climbed 69% year-over-year, which the company attributed to materially higher royalty income from Nubeqa.

Upgraded Full-Year Guidance

Ad

In a classic "beat-and-raise" scenario that often fuels strong investor sentiment, Orion's management also lifted its financial forecast for the full year 2026. The upgraded guidance signals that Nubeqa's commercial momentum is exceeding previous projections, bolstering confidence in the durability of its royalty stream.

The company now expects:

• Net Sales: Between EUR 2,000–2,100 million, an increase from the prior range of EUR 1,950–2,100 million.
• Operating Profit: Between EUR 650–750 million, up from the previous forecast of EUR 600–750 million.

Market Reaction

Orion's stock rally was a notable outlier in an otherwise negative trading session, with major U.S. indices like the S&P 500 and Nasdaq trading lower. The company-specific news provided a clear fundamental catalyst for investors to re-evaluate the stock, pushing its shares sharply higher against a broader risk-off market tone.